Podcast appearances and mentions of William J Sandborn

Guest: Xiaohong Wang, MD, PhD Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points. Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS)

In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.

Host: Caren Heller, MD Guest: William J. Sandborn, MD Clinical trials, among several critical purposes, are essential for the evaluation and approval of medication options for patients living with inflammatory bowel diseases. Despite this, only 6% of clinical trials are completed on time due to unfulfilled enrollment, often stemming to communication barriers between clinicians and patients. Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. William Sandborn, Professor of Medicine and Adjunct Professor of Surgery at the University of California-San Diego, about the many benefits that clinical trials can provide for IBD patients.

Host: Caren Heller, MD Guest: William J. Sandborn, MD Clinical trials, among several critical purposes, are essential for the evaluation and approval of medication options for patients living with inflammatory bowel diseases. Despite this, only 6% of clinical trials are completed on time due to unfulfilled enrollment, often stemming to communication barriers between clinicians and patients. Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. William Sandborn, Professor of Medicine and Adjunct Professor of Surgery at the University of California-San Diego, about the many benefits that clinical trials can provide for IBD patients.

Dr. William J. Sandborn discusses his manuscript, "Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease." To view the print version of this abstract go to http://bit.ly/PDdegz.

Guest: William J. Sandborn, MD Host: Mark DeLegge, MD The current treatment paradigm for Crohn's disease is a pyramid approach, where patients are given the safest medications before pursuing more aggressive strategies. New evidence suggests that Crohn's disease should be treated with the most effective medications first, such as anti-TNF therapies. But is a top-down strategy safe enough for most patients? Dr. William Sandborn, professor of medicine and gastrointestinal research at Mayo Clinic College of Medicine, describes the results of new Crohn's disease trials and research. Is using steroids to treat Crohn's disease an idea of the past, or are steroids still effective for certain patients? Dr. Mark DeLegge hosts.

Host: Mark DeLegge, MD Guest: William J. Sandborn, MD The current treatment paradigm for Crohn's disease is a pyramid approach, where patients are given the safest medications before pursuing more aggressive strategies. New evidence suggests that Crohn's disease should be treated with the most effective medications first, such as anti-TNF therapies. But is a top-down strategy safe enough for most patients? Dr. William Sandborn, professor of medicine and gastrointestinal research at Mayo Clinic College of Medicine, describes the results of new Crohn's disease trials and research. Is using steroids to treat Crohn's disease an idea of the past, or are steroids still effective for certain patients? Dr. Mark DeLegge hosts.